Page 1 | Search Results | Hematology, ASH Education Program

1-20 of 25

Sort by

Sort Order Select

Journal Articles

Beyond JAK-STAT: novel therapeutic targets in Ph-negative MPN

Aaron T. Gerds

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 407–414.

https://doi.org/10.1182/hematology.2019000048

Published: 2019

Journal Articles

What are the current treatment approaches for patients with polycythemia vera and essential thrombocythemia?

Alessandro M. Vannucchi, Paola Guglielmelli

Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 480–488.

https://doi.org/10.1182/asheducation-2017.1.480

Published: 2017

Journal Articles

Update from the latest WHO classification of MPNs: a user’s manual

Francesco Passamonti, Margherita Maffioli

Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 534–542.

https://doi.org/10.1182/asheducation-2016.1.534

Published: 2016

Journal Articles

Evidence for Janus kinase (JAK) inhibitors for the prevention of major morbid events in patients with myeloproliferative neoplasms (MPNs)

Naveen Pemmaraju, Ruben Mesa

Hematology Am Soc Hematol Educ Program (2015) 2015 (1): 649–651.

https://doi.org/10.1182/asheducation-2015.1.649

Published: 2015

Journal Articles

Management of symptoms in polycythemia vera and essential thrombocythemia patients

Deepti Radia, Holly L. Geyer

Hematology Am Soc Hematol Educ Program (2015) 2015 (1): 340–348.

https://doi.org/10.1182/asheducation-2015.1.340

Published: 2015

Journal Articles

Therapy for myeloproliferative neoplasms: when, which agent, and how?

Holly L. Geyer, Ruben A. Mesa

Hematology Am Soc Hematol Educ Program (2014) 2014 (1): 277–286.

https://doi.org/10.1182/asheducation-2014.1.277

Published: 2014

Journal Articles

Management of MPN beyond JAK2

Claire N. Harrison, Natalia Curto Garcia

Hematology Am Soc Hematol Educ Program (2014) 2014 (1): 348–354.

https://doi.org/10.1182/asheducation-2014.1.348

Published: 2014

Journal Articles

The spectrum of JAK2-positive myeloproliferative neoplasms

Jean-Jacques Kiladjian

Hematology Am Soc Hematol Educ Program (2012) 2012 (1): 561–566.

https://doi.org/10.1182/asheducation.V2012.1.561.3807838

Published: 2012

Journal Articles

Thrombotic disease in the myeloproliferative neoplasms

Anna Falanga, Marina Marchetti

Hematology Am Soc Hematol Educ Program (2012) 2012 (1): 571–581.

https://doi.org/10.1182/asheducation.V2012.1.571.3798557

Published: 2012

Journal Articles

Management of Myelofibrosis

Alessandro M. Vannucchi

Hematology Am Soc Hematol Educ Program (2011) 2011 (1): 222–230.

https://doi.org/10.1182/asheducation-2011.1.222

Published: 2011

Journal Articles

World Health Organization Classification, Evaluation, and Genetics of the Myeloproliferative Neoplasm Variants

James Vardiman, Elizabeth Hyjek

Hematology Am Soc Hematol Educ Program (2011) 2011 (1): 250–256.

https://doi.org/10.1182/asheducation-2011.1.250

Published: 2011

Journal Articles

Assessing New Therapies and Their Overall Impact in Myelofibrosis

Ruben A. Mesa

Hematology Am Soc Hematol Educ Program (2010) 2010 (1): 115–121.

https://doi.org/10.1182/asheducation-2010.1.115

Published: 2010

Journal Articles

Rethinking Disease Definitions and Therapeutic Strategies in Essential Thrombocythemia and Polycythemia Vera

Claire Harrison

Hematology Am Soc Hematol Educ Program (2010) 2010 (1): 129–134.

https://doi.org/10.1182/asheducation-2010.1.129

Published: 2010

Journal Articles

Pathogenesis and management of essential thrombocythemia

Philip A. Beer, Anthony R. Green

Hematology Am Soc Hematol Educ Program (2009) 2009 (1): 621–628.

https://doi.org/10.1182/asheducation-2009.1.621

Published: 2009

Journal Articles

Therapeutic potential of JAK2 inhibitors

Srdan Verstovsek

Hematology Am Soc Hematol Educ Program (2009) 2009 (1): 636–642.

https://doi.org/10.1182/asheducation-2009.1.636

Published: 2009

Journal Articles

The JAK2V617F Mutation in Polycythemia Vera and Other Myeloproliferative Disorders: One Mutation for Three Diseases?

Chloé James

Hematology Am Soc Hematol Educ Program (2008) 2008 (1): 69–75.

https://doi.org/10.1182/asheducation-2008.1.69

Published: 2008

Journal Articles

New Advances in the Pathogenesis and Therapy of Essential Thrombocythemia

Ross L. Levine, Mark Heaney

Hematology Am Soc Hematol Educ Program (2008) 2008 (1): 76–82.

https://doi.org/10.1182/asheducation-2008.1.76

Published: 2008

Journal Articles

Navigating the Evolving Paradigms in the Diagnosis and Treatment of Myeloproliferative Disorders

Ruben A. Mesa

Hematology Am Soc Hematol Educ Program (2007) 2007 (1): 355–362.

https://doi.org/10.1182/asheducation-2007.1.355

Published: 2007

Journal Articles

Classification, Diagnosis and Management of Myeloproliferative Disorders in the JAK2 V617F Era

Ayalew Tefferi

Hematology Am Soc Hematol Educ Program (2006) 2006 (1): 240–245.

https://doi.org/10.1182/asheducation-2006.1.240

Published: 2006

Journal Articles

Role of JAK-STAT Signaling in the Pathogenesis of Myeloproliferative Disorders

Ross L. Levine, Gerlinde Wernig

Hematology Am Soc Hematol Educ Program (2006) 2006 (1): 233–239.

https://doi.org/10.1182/asheducation-2006.1.233

Published: 2006

NARROW

Beyond JAK-STAT: novel therapeutic targets in Ph-negative MPN

What are the current treatment approaches for patients with polycythemia vera and essential thrombocythemia?

Update from the latest WHO classification of MPNs: a user’s manual

Evidence for Janus kinase (JAK) inhibitors for the prevention of major morbid events in patients with myeloproliferative neoplasms (MPNs)

Management of symptoms in polycythemia vera and essential thrombocythemia patients

Therapy for myeloproliferative neoplasms: when, which agent, and how?

Management of MPN beyond JAK2

The spectrum of JAK2-positive myeloproliferative neoplasms

Thrombotic disease in the myeloproliferative neoplasms

Management of Myelofibrosis

World Health Organization Classification, Evaluation, and Genetics of the Myeloproliferative Neoplasm Variants

Assessing New Therapies and Their Overall Impact in Myelofibrosis

Rethinking Disease Definitions and Therapeutic Strategies in Essential Thrombocythemia and Polycythemia Vera

Pathogenesis and management of essential thrombocythemia

Therapeutic potential of JAK2 inhibitors

The JAK2V617F Mutation in Polycythemia Vera and Other Myeloproliferative Disorders: One Mutation for Three Diseases?

New Advances in the Pathogenesis and Therapy of Essential Thrombocythemia

Navigating the Evolving Paradigms in the Diagnosis and Treatment of Myeloproliferative Disorders

Classification, Diagnosis and Management of Myeloproliferative Disorders in the JAK2 V617F Era

Role of JAK-STAT Signaling in the Pathogenesis of Myeloproliferative Disorders

ASH Publications

American Society of Hematology

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only